Responses

Download PDFPDF

Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome: a randomised 12 week controlled study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Reply to Dr Chan et al's comments on oral pilocarpine for ocular symptoms in Sjogren's syndrome
    • Alexandros A Drosos, Professor of Medicine/Rheumatology
    • Other Contributors:
      • Niki Tsifetaki, George Kitsos, Yannis Alamanos, Paraskevi V. Voulgari

    Dear Editor

    We thank Dr Chan and collaborators for their interest in our study and for their comments.[1] As concerns the patients’ selection, we excluded patients with serious medical problems such as heart, and lung diseases, as well as other ophthalmological disorders including glaucoma. Thus, none of our patients were treated with beta-blockers and none were on hormone replacement therapy which may exacerbate d...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Comments on oral pilocarpine for ocular symptoms in Sjõgren’s syndrome
    • Wai-Man Chan, Ophthalmologist
    • Other Contributors:
      • Carmen C. Chan, Dorothy S. Fan, Dennis S. Lam

    Dear Editor

    We read with great interest the study by Tsifetaki et al. on the efficacy and side effects of the use of oral pilocarpine for the treatment of ocular symptoms in Sjõgren’s syndrome.[1] In terms of patient selection, we noted the authors excluded patients with significant medical conditions, but we are not sure about the status of their concomitant medications. For women in their late 50s, suc...

    Show More
    Conflict of Interest:
    None declared.